Hepatitis B immunoglobulin (HBIG) is important in the management of hepatitis B virus (HBV) infection. Aiming to develop recombinant monoclonal antibodies as an alternative to HBIG, we report the successful identification of HBV surface antigen (HBsAg)-specific antibodies from a full-length human antibody library displayed on mammalian cell surface. Using total RNA of peripheral blood mononuclear cells of a natively immunized donor as template, the antibody repertoire was amplified. Combining four-way ligation and the Flp recombinase-mediated integration (Flp-In) system, we constructed a mammalian cell-based, fully human, full-length antibody display library in which each cell displayed only one kind of antibody molecule. By screening the cell library using fluorescence-activated cell sorting (FACS), eight cell clones that displayed HBsAg-specific antibodies on cell surfaces were identified. DNA sequence analysis of the antibody genes revealed three unique antibodies. FACS data indicated that fluorescent strength of expression (FSE), fluorescent strength of binding (FSB) and relative binding ability (RBA) were all different among them. These results demonstrated that by using our antibody mammalian display and screening platform, we can successfully identify antigen-specific antibodies from an immunized full-length antibody library. Therefore, this platform is very useful for the development of therapeutic antibodies.
INTRODUCTION
The hepatitis B virus (HBV) causes one of the most common infections in the world.
1,2 Two billion people have been infected with the virus, and about 350 million people are suffering from chronic HBV infection. More than one million people are estimated to die every year with liver failure, cirrhosis and hepatocellular carcinoma associated with HBV infection. Widely used, vaccination has been effective in preventing HBV infection. 3, 4 Hepatitis B immunoglobulin (HBIG) is also important in the management of HBV infection. 5, 6 Since vertical transmission is responsible for about 40%-50% of HBV carriers, 5 newborns of mothers who are HBV surface antigen (HBsAg)-positive are generally required to receive HBIG and hepatitis B vaccine within 24 h following delivery and complete the whole regimen of recommended vaccination injections. 7 Liver transplantation is an effective method for end-stage liver disease management, and many people with liver diseases related to HBV receive liver transplantation. However, liver transplantation cannot eliminate HBV infection in the blood or in other organs. 8 With the inhibition of immunity, HBV reinfection occurs frequently, and it is more aggressive than before liver transplantation. Under these conditions, acute liver failure, fibrous cholestasis hepatitis and liver cirrhosis can follow with 50% mortality after 2 years. 9, 10 Combination therapy with HBIG and lamivudine was shown to be an effective management therapy. 11 Medical staff having contact with the blood or blood fluids of HBV carriers should receive HBIG immediately, if the titers of their hepatitis B surface antigenspecific antibody (anti-HBs) are lower than 10 mIU/ml. 7 HBIG is commonly prepared from the blood plasma of anti-HBspositive persons through natural infection or vaccination. Being a human plasma-derived product, HBIG is inconvenient for large-scale acquisition. Also, there are risks associated with blood-borne infectious pathogens, such as hepatitis C virus and human immunodeficiency virus.
So far, scientists have applied multiple strategies in the effort to find a way to produce HBIG safely and more effectively. A variety of HBV donor-specific phage display antibody libraries have been constructed in order to screen, select and develop HBsAg-specific monoclonal antibody therapeutics. 12, 13 Using phage display technology, the complex structure of full-length antibodies have previously necessitated a cumbersome 'divide and conquer' approach whereby antibodies are first dissected into fragments that can be engineered in microorganisms, followed by 'stitching back' the optimized fragments into the full-length form for production in mammalian cells.
14 Most recently, mammalian display promises to enable rapid and direct screening of full-length antibodies. Furthermore, since the selected antibody can be directly produced in mammalian cells, scientific research is further benefited by savings in both time and money. However, most of these systems display multiple copies of antibodies with different specificities on a single cell surface, making it difficult to identify and isolate antibodies with a desired property. These limitations significantly hamper the application of mammalian display technology in the development of therapeutic antibodies. 15 Some researchers have tried to overcome these limitations by sufficiently diluting the antibody gene library plasmids with non-library plasmids prior to transfection. Under well-controlled transfection conditions, the majority of the transfectants display one kind of antibody on the cell surface. 16 Nevertheless, the dilution ratio and transfection efficiency were not very easily controlled.
To overcome these challenges, we have successfully developed a platform in which only one specific antibody can be displayed on each mammalian cell surface. 15 Coupled with fluorescence-activated cell sorting (FACS) and two-color staining, antibody with antigen specificity can be selected, and the affinity can be analyzed directly by detecting fluorescent strength of expression (FSE), fluorescent strength of binding (FSB) and relative binding ability (RBA). 15 Using the vector pDGB-HC-TM and the enzymes BsmBI and SfiI, we have also developed a method to construct large full-length antibody libraries with sizes of 10 10 -10 11 within 2-8 weeks. [17] [18] [19] [20] Using the one-step fourway ligation method and the vector pDGB4, we can construct highly efficient antibody libraries with sufficient stability to display fulllength antibodies on mammalian cell surfaces. When coupled with the Flp recombinase-mediated integration (Flp-In) 21 system, each cell displays only one kind of antibody molecule, 15, 22, 23 which may be helpful for the screening of high-affinity antibodies with biological function.
Here we report the construction of a fully human, full-length mammalian cell surface-displayed antibody library of a healthy volunteer and the successful identification of HBsAg-specific antibodies from the library.
MATERIALS AND METHODS

Reagents and cell lines
Primers were synthesized by Invitrogen (San Diego, CA, USA). T4 DNA ligase and restriction enzymes were purchased from Fermentas (Hanover, MD, USA). Ready-to-use Taq DNA polymerase (23 Master Mix) came from Promega (San Luis Obispo, CA, USA). Cell transfection reagent was kindly provided by Dgen Biotech Ltd (Hong Kong, China). The Flp-In system, including vector pOG44, Flp-In Chinese hamster ovary (FCHO) cell line and related cell maintenance media, was bought from Invitrogen (Carlsbad, CA, USA). Antibody reagents were bought from BD Pharmingen (San Diego, CA, USA). FCHO cells and 293-T cells (ATCC, Manassas, VA, USA) were maintained in Ham's F12 or Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Cell dissociation buffer was purchased from Invitrogen. Vector pDGB-HC-TM and vector pDGB4 had already been constructed as described previously. 19, 22 Miniprep, maxiprep and gel extraction Using the kits bought from Axygen (Union City, NJ, USA), experiments were performed according to the manufacturer's instructions.
DNA digestion and fragment purification Vector DNA was isolated from overnight cultures of Escherichia coli bacteria. DNA fragments were separated through electrophoresis in 1% agarose gel after digestion with proper restriction enzymes. The target DNA fragments were later isolated as described previously. 24 Isolation of human peripheral blood mononuclear cells and amplification of antibody genes Fifty milliliters of peripheral blood were obtained from a healthy volunteer who had recovered from hepatitis B virus infection. The protocol for collection of blood for this study was approved by Medical Ethics Committee of Nanfang Hospital and the volunteer signed the written informed consent before blood collection. ELISA analysis of his blood serum was performed by Nanfang Hospital and showed positive result of anti-HBsAg antibody. Peripheral blood mononuclear cells (PBMCs) were collected by gradient centrifugation at 400g for 20 min in a swing-bucket rotor, and PBMC layer was carefully transferred to a new tube and washed twice using phosphate-buffered saline. Total RNA of PBMCs was isolated using RNesay Mini Kit according to manufacturer's instructions. Using the RNA as template, the antibody genes were amplified by twostep reverse transcription (RT)-PCR. RT was carried out with 500 nM specific primer following Promega's instructions. The RT products were used as template in PCR amplification. In a 50 ml tube, 200 nM forward and reverse primers were mixed with 2 ml of RT products and 25 ml of 23 Master Mix. 19 Amplification conditions were as follows: 94 uC for 5 min to denature the template, followed by 35 cycles of 30 s at 94 uC, 30 s at 55 uC and extension at 72 uC for 1 min per 1 kb length of DNA to be amplified, ending with 7 min of extension at 72 uC. PCR products were separated by electrophoresis on a 1% agarose gel and purified. The targeted fragments were digested by proper restriction enzymes according to experimental needs, purified by electrophoresis in another agarose gel, and then used in ligation.
Vector ligation and transformation
About 100 ng of total vector and insert fragments were mixed in a total volume of 10 ml with one unit of T4 DNA ligase. After ligation for at least 2 h, 1 ml of ligation mixture was used in transformation with 50 ml of bacteria-competent cells by standard procedure. The proper amount of bacterial solutions was plated on LB-ampicillin plate and cultured at 37 uC overnight. The colonies were counted, and the transformation efficiencies and library sizes were calculated.
Transfection and selection
Transfection was performed according to experimental needs with either FCHO cells or 293-T cells. Typically, transient transfection was performed in a 12-well plate, unless otherwise stated. The day before transfection, 4310 5 cells were seeded in each well. The transfection reagent (5 mg) and DNA (2 mg) were separately diluted in 100 ml of Dulbecco's modified Eagle's medium each and then mixed well. The mixture was incubated for 30 min at room temperature and directly added into each well without changing the culture medium; then cells were commonly incubated at 37 uC. Six hours later, the medium was Identification of human antibody specific for HBV C-Z Li et al 185 changed with fresh culture medium. At 48-72 hours post-transfection, the antibody expression was analyzed by FACS. For stable transfection using a T-75 flask, 8310 6 cells were seeded the day before transfection. Thirty-five micrograms of vector DNA in total (20 mg of antibody library plus 15 mg of pOG44) and 105 mg of transfection reagent were separately diluted in 1 ml of Dulbecco's modified Eagle's medium each and then mixed. The mixture was incubated at room temperature for 30 min and directly added into the flask without changing the culture medium. After 24 hours of incubation at 37 uC, most of the cells were split with a ratio of 1 : 10 and small amount of cell suspension was used for serial dilution of 1 : 100, 1 : 1000 and 1 : 10 000. Hygromycin B was added in the medium 24 hours post-split to a concentration of 500 mg/ ml. After selection for 10-12 days, the hygromycin B-resistant cell clones were collected as the stable cell library for FACS analysis and selection of specific antibodies. The cell clones in the flask of proper dilution were counted and the total library size was calculated accordingly.
Preparation of FITC fluorescence-labeled HBsAg Genetic HBsAg protein was purchased from Keyuezhongkai (Beijing, China). Fluoro Tag FITC Conjugation Kit was purchased from SigmaAldrich (St Louis, MO, USA). HBsAg protein was prepared in 0.1 M carbonate-bicarbonate buffer at a concentration of 5.0 mg/ml. One milligram of the protein was used for FITC labeling according to manufacturer's instructions. The concentration of FITC fluorescence-labeled HBsAg (FITC-H) was 1.8 mg/ml, and the fluorescein/protein molar ratio (F/P) was 1.18 : 1, which means that there were 1.18 FITC fluorescein molecules on each HBsAg molecule.
FACS analysis and selection of cell library FCHO cells or 293-T cells were dissociated by cell dissociation buffer, followed by one wash using staining buffer (2% fetal bovine serum in phosphate-buffered saline). Then, cells were stained on ice by PE fluorescence-labeled anti-human kappa chain antibody (PE-K) only or FITC-H added, according to experimental needs. After staining for 30 min, cells were washed and resuspended in staining buffer for FACS analysis. The FACS data were analyzed using FCS Express V3 (De Novo Software, Los Angeles, CA, USA). FSE, FSB and RBA were calculated as described previously. 15 Single cells with specific binding to HBsAg were sorted into a 96-well plate for further analysis, as needed.
RESULTS
Construction and analysis of primary heavy chain (HC) and light chain (LC) libraries
The primary fully human, full-length antibody gene libraries were constructed as described previously. 19 Using total RNA isolated from donor's PBMC as template, the full-length kappa LC repertoire and variable domain of HC (VH) repertoire were amplified by two-step RT-PCR procedure. PCR primers were designed according to the sequence information of V-base as described (http://vbase.mrccpe.cam.ac.uk/) and contained comparable restriction endonucleaserecognizing sequences at the 59-ends. 19, 20 The forward primers, from 59-to 39-, contain restriction endonuclease-recognizing sequences, Kozak sequence (CCACC), start codon and gene-specific sequences. The reverse primers contain restriction endonuclease-recognizing sequences and gene-specific sequence. After PCR amplification, the fragments were digested by proper restriction endonuclease. After insertion of VH and LC into vector pDGB-HC-TM separately, an HC (IgG1) library and a kappa chain library with sizes of 1.02310 6 and 1.78310 5 were constructed, respectively. The combinatory library size is 1.82310 11 ((1.02310 6 )3(1. 78310 5 )). To assess the quality of the library, 10 clones each were randomly chosen from HC and LC libraries for sequence analysis. The results showed that six HC clones had correct reading frame, coding for six unique VH (Figure 1a ) and that nine LC clones have correct reading Identification of human antibody specific for HBV C-Z Li et al 186 frame, coding for eight unique LCk (Figure 1b) . According to the sequence results, the combinatory library diversity is 8.71310 10 . After cotransfection of these two libraries into 293T cells, the antibody expression was analyzed by FACS. Cells were stained by PE-K. Results showed that 75.23% of the cells had detectable antibody expression on the cell surface (Figure 1c ).
Construction and screening of secondary fully human, full-length antibody mammalian display library
The secondary fully human, full-length antibody gene library was constructed by four-way ligation. 22 The gene fragments from primary HC library (BsmBI digested) and primary LC library (SfiI digested) were simultaneously cloned into vector pDGB4 by four-way ligation. After transformation, the number of bacterial clones was counted and transformation efficiency was calculated as described previously. 19, 22 The size of the secondary library was 2.20310 5 with a background of 0.40%.
By stable transfection of the secondary library into FCHO cells, a stable antibody display library was constructed with a size of 4.32310 5 , calculated by counting the cell clones. FACS analysis showed that 40.12% of FCHO cells in the library could display detectable full-length antibodies on cell surfaces (Figure 2a) .
The FITC-conjugated HBsAg (FITC-H) was prepared as described in the section on 'Materials and methods'. After labeling with PE-K plus FITC-H, the FCHO cell library was analyzed by FACS. In Figure 2b , 1.52% of the cells, which are PE-K and FITC-H doublepositive, were sorted out and expanded for a second round of FACS analysis and sorting. After two rounds of FACS screening, the percentage of PE and FITC double-positive cells rose to 10.31% (Figure 2c) .
As shown in Figure 2c , 0.10% double-positive cells were sorted into two 96-well plates for single-cell cloning and 65 sorted cell clones were successfully grown out. The cells were labeled with PE-K plus FITC-H and analyzed by FACS. The results showed that cells displaying non-specific antibodies exhibited only PE-K or/and FITC-G signals but no FITC-H signal (Figure 3b-d) , indicating that the cells express full-length antibodies which has no binding ability to HBsAg and there are no other molecules on cell surface which can bind to HBsAg specifically or non-specifically. The results of double staining of 
Sequences and binding ability of selected clones
Total RNAs were isolated from the 8 FCHO cell clones. VH and LC were amplified by RT-PCR and cloned into pDGB4. Sequence analysis shows that #1, #2, #3, #5, #6 and #7 cell clones coded the same amino-acid sequence, while clones #4 and #8 coded two unique amino acid sequences (Figure 4 ). BLAST analysis of amino-acid sequences through GeneBank database showed that the amino-acid sequences of the three clones (#1, #4 and #8) were unique. To confirm that the antibodies cloned bind to HBsAg, the plasmid DNAs of clones #1, #4 and #8 were transiently transfected into FCHO cells. FACS analysis of the cell clones double-stained by PE-K and FITC-H demonstrated the HBsAg-specific binding of these antibodies ( Figure 5 ). Clone #1 shows the highest RBA (Table 1) . DISCUSSION A key step in the development of antibody therapy is the identification of target antigen-specific antibodies. Hybridoma [25] [26] [27] technology is commonly used in screening and selecting these antibodies. In most situations, they are nonhuman antibodies, which need to be humanized for further development as therapeutics. Phage display 28, 29 is a newly developed antibody screening technology, and it is now the most widely used antibody display technology in developing therapeutic antibodies. However, because of the non-full-length display and the non-mammalian property, the development of identified antibody fragments is challenged by high production costs and a low rate of success.
To address these issues, we have utilized a newly developed mammalian display technology to identify HBsAg-specific antibodies. Using total RNA of a natively immunized donor as template, the antibody repertoire was amplified by RT-PCR and fully human, full-length antibody display libraries were constructed. Three unique HBsAg-specific antibodies were identified from the established FCHO cell library. Because they are fully human, full-length antibodies, they can be easily expressed from CHO cells, with no further need to humanize or convert fragments to full length, if they are proved to be candidates for further development of therapeutic antibodies.
It has been reported that the Flp-In single integration-based mammalian display system can be successfully used in affinity maturation by mammalian display technology 15 and is a more powerful platform in identification of antigen-specific antibodies compared to the multiple integration system used by other researchers. 16, 30 Using this system, cell clones expressing antigen-specific antibodies can be efficiently screened and selected by single-cell sorting after only brief enrichment.
In the present report, separate primary HC and LC libraries were constructed with the goal of preserving the highest diversity of HC and LC, thus permitting us to reserve the original materials in stock for further manipulation should we, at any time, fail to construct a singleintegration, dual-expression cassette, full-length antibody display FCHO library. According to the sequence analysis of single DNA clones, 6/10 of heavy chain clones ( Figure 1a ) and 9/10 of light chain clones (Figure 1b) are expressible. Theoretically, 54% of the DNA clones in the secondary DNA library would be expressible. In other words, 54% of the FCHO cells, after stable single integration, will express full-length antibodies. Results show that about 40% of the cells express detectable full-length antibodies on FCHO cell surfaces, which roughly agrees with theoretical calculation, considering that not every expressible DNA clone will express and display enough antibody molecules on the cell surface to be detectable after integration into the cell genome.
The secondary library has a size of 2.2310 5 in bacteria transformants and 4.32310 5 in FCHO cell clones. Because 6/10 of HC clones ( Figure 1a ) and 8/10 of LC clones (Figure 1b) are unique, the diversity of the secondary library is about 1310 5 , and the cell library has coverage of four times the diversity. The results demonstrate that an immunized antibody library of 10 5 in diversity is large enough for the identification of target antigen-specific antibodies. For antibodies with some specific functions, such as antibody-dependent cellmediated cytotoxicity or complement-dependent cytotoxicity, a library with more diversity may be required. The primary libraries provide the potential to meet these needs because our primary library Identification of human antibody specific for HBV C-Z Li et al 189 has a combinatory library size of 10 11 and a combinatory diversity of more than 10 10 . Coupled with FACS, we successfully screened eight cell clones which could stably display antibody binding to HBsAg. Sequence analysis results revealed three unique antibodies among these eight cell clones. Antibody from cell #1 has the highest RBA among the three antibodies. To our knowledge, it is the first time to directly identify antigenspecific full-length human antibodies by the Flp-In single integration-based mammalian display platform 15 from mammalian cell surface displayed full-length antibody library constructed using materials from immunized personal. These results confirm that our antibody mammalian display and screening platform can be successfully used in specific antibody screening and will be very helpful in the development of therapeutic antibodies.
